Skip Navigation


Rheumatology Advance Access originally published online on January 18, 2005
Rheumatology 2005 44(3):410-411; doi:10.1093/rheumatology/keh503
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
44/3/410    most recent
keh503v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (7)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Nehme-Schuster, H.
Right arrow Articles by Martin, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nehme-Schuster, H.
Right arrow Articles by Martin, T.
Related Collections
Right arrow Systemic Lupus Erythematosus and Autoimmunity
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology Vol. 44 No. 3 © British Society for Rheumatology 2005; all rights reserved

LETTER TO THE EDITOR

Rituximab inefficiency during type I cryoglobulinaemia

H. Nehme-Schuster, A.-S. Korganow, J.-L. Pasquali and T. Martin

Service de Medecine Interne et d’Immunologie Clinique, 1, place de l’Hôpital, 67091 Strasbourg, France

Correspondence to: H. Nehme-Schuster. E-mail: Helene.Nehme@chru-strasbourg.fr

The first 10% of the full text of this article appears below.

SIR, Rituximab, a chimeric antibody binding to the human B-cell antigen CD20, is effective and safe as adjuvant or primary therapy in several B-cell lymphomas. It has also been used in other haematological disorders sustained by B-cell lymphoproliferation and appears promising in some autoimmune diseases. Rituximab also has proved efficiency during type II mixed cryoglobulinaemia (Cg) [1, 2], reducing cryoglobulin levels and significantly improving clinical parameters in . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
H. Cohen, S. Green, S. Jones, N. Amos, and B. D. William
Lack of efficacy of Rituximab in a patient with essential mixed cryoglobulinaemia
Rheumatology, February 1, 2007; 46(2): 366 - 367.
[Full Text] [PDF]